Wockhardt · NSE: WOCKPHARMA · BSE: 532300
Q2 FY25 results · Jul–Sep 2024
Wockhardt reported revenue from operations of ₹809.00 crore (up 7.4% from Q2 FY24) and net loss of ₹16.00 crore for Q2 FY25 (Jul–Sep 2024), on a consolidated basis.
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 809.00 | 753.00 | +7.4% | 739.00 | +9.5% |
| Other income | 9.00 | 24.00 | −62.5% | 30.00 | −70.0% |
| Total income | 818.00 | 777.00 | +5.3% | 769.00 | +6.4% |
| Profit before tax | (9.00) | (35.00) | Loss narrowed | (6.00) | Loss widened |
| Net profit for the period | (16.00) | (73.00) | Loss narrowed | (16.00) | Unchanged |
| Attributable to shareholders of the company | (22.00) | (77.00) | Loss narrowed | (14.00) | Loss widened |
| EPS, basic (₹) | (1.47) | (5.37) | Loss narrowed | (0.95) | Loss widened |
| Net margin (%) | -2.0 | -9.7 | -2.2 |
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 370.00 | 260.00 | +42.3% | 352.00 | +5.1% |
| Other income | 11.00 | 6.00 | +83.3% | 27.00 | −59.3% |
| Total income | 381.00 | 266.00 | +43.2% | 379.00 | +0.5% |
| Profit before tax | (36.00) | (107.00) | Loss narrowed | 6.00 | Turned loss |
| Net profit for the period | (36.00) | (107.00) | Loss narrowed | 6.00 | Turned loss |
| EPS, basic (₹) | (2.34) | (7.39) | Loss narrowed | 0.39 | Turned loss |
| Net margin (%) | -9.7 | -41.2 | 1.7 |
Consolidated
- Filed with BSE
- 13 Nov 2024, 17:59 IST
- Board meeting
- 13 Nov 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 13 Nov 2024, 17:59 IST
- Board meeting
- 13 Nov 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE